Compare TransMedics Group Inc (TMDX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Zimmer Biomet Holdings Inc — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.2× TransMedics Group Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TMDX | ZBH | |
|---|---|---|
Market Cap | $2.74B | $16.95B |
Volume | 949,331 | 2,505,240 |
Sector | Health | Health |
52-Week High | $150.42 | $103.98 |
52-Week Low | $61.99 | $79.58 |
Typical Hold Time | 24 Days | 89 Days |
Enterprise Value | $3.13B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
